AMENDMENTS TO THE CLAIMS

1. (Currently amended) A ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any~~compound or salt thereof represented by one or more of the following ~~compounds~~formulas:



Supragenus A;



Supragenus B;



Supragenus C; and



Supragenus D;

wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;

wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;

wherein n is a number from one to four;

wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

2. (Currently amended) ~~A pharmaceutical composition~~The compound or salt thereof of Claim 1, wherein the Supragenus A-D are represented by the formulas:



Genus A1;



Genus A2;



Genus A3;



Genus A4;



Genus A5



Genus B1;



Genus B2;



Genus B3;



Genus B4;



Genus C1;



Genus C2;



Genus C3;



Genus C4;



Genus D1;



Genus D2;



Genus D3; and



Genus D4;

wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;

wherein A is selected from the group consisting of H and halogen;

wherein n is a number from one to four;

wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

3. (Currently amended) The compound or salt thereof of Claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl and norbornyl.

4. (Currently amended) The compound or salt thereof of Claim 1, wherein said heteroaryl and said substituted heteroaryl is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophines, benzofurans, parathiazines, pyrans[[,]] and

~~chromenes, pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding heterocyclies~~.

5. (Cancelled)

6. (Currently amended) The compound or salt thereof ~~pharmaceutical composition~~ of Claim 1, wherein R_1 and R_2 are independently selected from the group consisting of:



7. (Currently amended) The ~~pharmaceutical composition~~compound or salt thereof of Claim 1 ~~comprising a compound~~ selected from the group consisting of compounds S-1 to S-25.

8. (Currently amended) A ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any~~compound or salt thereof represented by ~~one or more of~~ the following ~~compounds~~formula:



;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

9. (Currently amended) The ~~pharmaceutical composition~~compound or salt thereof of Claim 8 ~~comprising a compound~~ selected from the group consisting of compounds S-4, S-5, S-6, S-7, S-8, S-11, S-13, S-15 and S-16.

10. (Currently amended) The ~~pharmaceutical composition~~compound or salt thereof of Claim 9 ~~comprising~~ represented by the compound S-7.

11. (Currently amended) A compound or salt thereof represented by ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of~~ the following ~~compounds~~formula:



;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

12. (Currently amended) The compound or salt thereof ~~pharmaceutical composition~~ of Claim 11 ~~comprising a compound~~ selected from the group consisting of compounds S-17, S-19, S-20[[,]] and S-21.

13. (Currently amended) A compound or salt thereof represented by ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of~~ the following ~~compounds~~formula:



;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl

contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

14. (Currently amended) The compound or salt thereof ~~pharmaceutical composition of~~ Claim 13 ~~comprising~~ represented by the compound S-24.

15. (Currently amended) A compound or salt thereof represented by ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of~~ the following ~~compounds~~formula:



;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

16. (Currently amended) The compound or salt thereof ~~pharmaceutical composition of~~ Claim 15 ~~comprising~~ represented by the compound S-25.

17. (Currently amended) A compound or salt thereof represented by ~~pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of~~ the following ~~compounds~~formula:



;

wherein T and X are independently selected from N or C, and wherein one of T and X is N;

wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;

wherein n is a number from one to four;

wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and

wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.

18. (Withdrawn – currently amended) A method for treating or preventing an allergic reaction and/or for inhibiting cytokines or leukocytes in a mammal comprising administering an effective amount of any one or more of the ~~following~~ compounds or salts thereof of Claim 1.[[:]]



~~Supragenus A;~~



~~Supragenus B;~~



~~Supragenus C; and~~



~~Supragenus D;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;~~

~~wherein n is a number from one to four;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and~~

~~substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~

19. (Withdrawn) The method of Claim 18 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

20. (Withdrawn) The method of Claim 19, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2-adrenergic agonist, a long-acting β_2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

21. (Withdrawn) The method of Claim 19, wherein said at least one additional ingredient is combined with said compound in a pharmaceutically acceptable diluent and co-administered to the mammal.

22. (Withdrawn) The method of Claim 18, wherein said compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

23. (Withdrawn) The method of Claim 22, wherein said dose is administered in divided doses at regular periodic intervals.

24. (Withdrawn) The method of Claim 23, wherein said regular periodic intervals occur daily.

25. (Withdrawn – currently amended) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of any one or more of the ~~following~~ compounds or salt thereof of Claim 1.[[:]]



~~Supragenus A;~~



~~Supragenus B;~~



~~Supragenus C; and~~



~~Supragenus D;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;~~

~~wherein n is a number from one to four;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~

26. (Withdrawn) The method of Claim 25 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.

27. (Withdrawn) The method of Claim 26, wherein said additional ingredient is selected from the group consisting of a short-acting β_2-adrenergic agonist, a long-acting β_2-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

28. (Withdrawn – currently amended) A method for inhibiting cellular proliferation in a mammal comprising administering an effective amount of any one or more of the ~~following~~ compounds or salts thereof of Claim 1[[:]]



~~Supragenus A;~~



~~Supragenus B;~~



~~Supragenus C; and~~



~~Supragenus D;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;~~

~~wherein n is a number from one to four;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino-alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur.~~

29. (Withdrawn) The method of Claim 28 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.

30. (Withdrawn) The method of Claim 29, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.

31. (Withdrawn) The method of Claim 29, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.

32. (Withdrawn) The method of Claim 29, wherein said at least one additional ingredient is combined with said compound in a pharmaceutically acceptable diluent and co-administered to the mammal.

33. (Withdrawn) The method of Claim 28, wherein said compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

34. (Withdrawn) The method of Claim 33, wherein said dose is administered in divided doses at regular periodic intervals.

35. (Withdrawn) The method of Claim 34, wherein said regular periodic intervals occur daily.

36. (Withdrawn) The method of Claim 28 further comprising administering at least one other therapy which is effective in ameliorating at least one symptom associated with cellular hyperproliferation.

37. (Withdrawn) The method of Claim 36, wherein said therapy is an anti-cancer therapy.

38. (Withdrawn) The method of Claim 36, wherein said therapy is selected from the group consisting of radiation, immunotherapy, gene therapy, and surgery.

39. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus A as defined in Claim 1 comprising:



~~Supragenus A;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;~~

~~wherein n is a number from one to four;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

cyclizing the compound with a formula:  with use of an acid to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus A.

40. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus A as defined in Claim 1 comprising:



~~Supragenus A;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein A is selected from the group consisting of H, halogen, and $CONHR_1$;~~

~~wherein n is a number from one to four;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl~~

~~contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus A.

41. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus B as defined in Claim 1 comprising:



~~Supragenus B;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics,~~

~~phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

cyclizing the compound with a formula:  to form to form a compound of Supragenus B.

42. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supreagenus B as defined in Claim 1 comprising:



~~Supragenus B;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and~~

~~substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form to form a compound of Supragenus B.

43. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus C as defined in Claim 1 comprising:



~~Supragenus C;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

cyclizing the compound with a formula:  with use of an acid to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus C.

44. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus C as defined in Claim 1 comprising:



~~Supragenus C;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl,~~

~~dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus C.

45. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus D as defined in Claim 1 compriring:

 ~~Supragenus D;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said~~

~~substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

cyclizing the compound with a formula:  with use of an acid to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus D.

46. (Withdrawn – currently amended) A method of preparing a compound or salt thereof ~~having the formula~~of Supragenus D as defined in Claim 1 comprising:



~~Supragenus D;~~

~~wherein Q, T, X, and Z are independently selected from N or C, and wherein one of Q, T, X, and Z is N;~~

~~wherein L and M are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF_3, OCF_3, $CONH_2$, CONHR and $NHCOR_1$;~~

~~wherein R is selected from the group consisting of H, C_1-C_5 alkyl, benzyl, p-fluorobenzyl and di-alkylamino alkyl, wherein said C_1-C_5 alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;~~

~~wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatic groups, substitued polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said substituted polycyclic aliphatic groups, substituted phenyl, substituted naphthyl and substituted heteroaryl contain 1-3 substituents, wherein said substituent is selected from the group consisting of H, halogens, polyhalogens, alkoxy group, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, carbonyl, OH, OCH_3, COOH, COOR′ COR′, CN, CF_3, OCF_3, NO_2, NR′R′, NHCOR′ and CONR′R′; and~~

~~wherein R′ is selected from the group consisting of H, alkyl, substituted alkyl, C_3-C_9 cycloalkyl, substituted C_3-C_9 cycloalkyl, polycyclic aliphatics, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;~~

~~wherein said method comprises steps:~~

reacting a compound with a formula:  with ammonium hydroxide to form a compound with a formula:  ;

reacting the compound with a formula:  with diammonium sulfide to form a compound with a formula:  ;

reacting the compound with a formula:  with a compound with a formula:  to form a compound with a formula:  ;

reducing the compound with a formula:  to form a compound with a formula:  ; and

reacting the compound with a formula:  with an acyl chloride to form a compound of Supragenus D.

47. (New) A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal comprising any one or more of the compounds or salts thereof of Claim 1.

48. (New) The pharmaceutical composition of Claim 47, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction and/or cell proliferation.

49. (New) A compound or salt thereof represented by the following formula:



S-5.